Goldman Sachs Maintains Buy on Calumet, Raises Price Target to $34
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:CLMT) with a Buy and raises the price target from $24 to $34.
Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:CLMT) with a Buy and raises the price target from $24 to $34.